2007 Revised Empiric Treatment IDSA/ATS Guidelines for CAP
2007 Revised Empiric Treatment IDSA/ATS Guidelines for CAP
Special Report
By Carol A. Kemper, MD, FACP, Clinical Associate Professor of Medicine, Stanford University, Division of Infectious Diseases; Santa Clara Valley Medical Center, Section Editor, Updates; Section Editor, HIV, is Associate Editor for Infectious Disease Alert.
Dr. Kemper reports no financial relationship relevant to this field of study.
Sources: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007, 44(S2), S27-S72; www.idsociety.org/guidelines.
Pines JM. Measuring antibiotic timing for pneumonia in the emergency department: Another nail in the coffin. Ann Emerg Med.2007, Epub ahead of print.
Since the publication of the initial IDSA Guidelines for the management of community acquired pneumonia in 2003, and their implementation by JHACO and the Centers for Medicare and Medicaid Services (CMS) in 2004 as a "quality standard" for hospital care and reimbursement, hospital administrators have been scrambling to improve their numbers. Notably, the 2003 Guideline advocated the administration of appropriate antibiotics within 4 hours of arrival to the emergency department (ED) for patients with possible CAP. For reimbursement, hospitals were required by the Joint Hospital Commission and CMS to attain > 90% compliance with these measures. "Non-compliance" (ie, less than 90% compliance) resulted in a "low score" for the hospital which, to the horror of our hospital administrators, was published on the Internet. This score had no relevance to clinical data or the actual number of patients who received appropriate care. To improve their performance, some ED physicians received financial incentives for speedier diagnosis and treatment, and those physicians that failed to prescribe one of the 4 specified beta-lactams, or perhaps gave an extra antibiotic for poorly documented reasons, were considered "non-compliant."
As a result, some hospitals have moved toward the blanket administration of a specified antibiotic for any individual walking in to the ED with possible CAP. Administrators at one of our hospitals altered the computer ordering system so that ED physicians were given one and only one choice of initial empiric therapy, ceftriaxone and azithromycin. One administrator was overheard to say of the ED physicians "I don't want them to think, I just want them to order the — antibiotic."
Clinicians and researchers are increasingly concerned about this misguided and potentially dangerous intrusion of government bodies into healthcare decision-making. Strict adherence to guidelines can have unintended and adverse consequences for patient care, including the inappropriate administration overuse of antibiotics, an increase in health care costs, adverse outcomes and medication reactions, and increased antibacterial resistance. Imagine the consequences for antibacterial resistance if every ED used levofloxacin for every person walking through the ER with cough and fever. In addition, evidence suggests that the all-too-frequent administration of quinolones has contributed to the rise of MRSA.
The basis for the initial recommendation (that antibiotics be administered within 4 hours) grew from a general impression that patients, especially those that are ill, probably do better the sooner they receive antibiotic therapy. However, there is notably little clinical data to support this impression. Two retrospective studies found an association between the administration of antibiotics within 8 hours of presentation and severity-adjusted outcomes; subsequent analyses found that < 4 hours was associated with a lower mortality. But retrospective data can readily be confounded by other factors, both studies actually found that patients who received antibiotics within 0-2 hours did worse, and the degree of survival benefit was small. Other studies have shown that atypical presentations of pneumonia, which may lack initial radiographic evidence of an infiltrate, resulting in possible delays in treatment, were associated with twice the mortality. But these are the very patients to which the de facto 4-hour rule might fail to apply.
Good guidelines are useful tools, and their appropriate use may result in improved outcomes. A large 5-year clinical trial found that the use of guidelines in the treatment of CAP in 28,700 patients resulted in a 3.2% lower 30-day mortality rate. However, no study has demonstrated that the implementation of a single set of "rules" in the ED has improved outcomes. For this reason, the latest IDSA guideline states "CAP guidelines should address a comprehensive set of elements in the process of care." Deviations from the guidelines are natural, and by the very nature of medicine, should occur 5% to 20% of the time. The 2007 modified recommendations for initial empiric antibacterial treatment include:
- For patients with CAP requiring hospitalization without healthcare associated PNA, the administration of (a) a respiratory fluoroquinolone or (b) a beta-lactam plus a macrolide (preferred beta-lactam agents include cefotaxime, ceftriaxone, and ampicillin; ertapenem for selected patients with risk factors for gram-negative infection; a respiratory fluoroquinolone should be used for PCN-allergic patients (note the wording "preferred").
- For patients admitted through the ED, the first antibiotic dose should be administered in the ED. This is a practical recommendation for which there is only limited anecdotal clinical evidence. The IDSA/ATS Committee did not feel a specific time window for delivery of the first dose of antibiotics should be recommended. Rather, a practical decision was made to administer treatment as soon as possible after the diagnosis of CAP was considered likely for those patients being admitted through the ED.
- The 2007 guidelines do account for the increasing prevalence of methicillin-resistant Staphylococcus aureus (CA-MRSA) as a cause of community acquired pneumonia, even in patients without identifiable risk factors. Patients hospitalized with severe CAP should be evaluated for CA-MRSA, with appropriate cultures, and administered empiric vancomycin in addition to the recombinant antibiotics for CAP.
- The newer guidelines also provide revised recommendations on duration of treatment.
- A new assessment tool with 5 parameters is provided to gauge whether a patient should be considered for admission to hospital. The previous pneumonia severity of illness (PSI) score, which was based on 20 different parameters, proved overly complex.
Infectious disease and infection control personnel have a responsibility to encourage the thoughtful implementation of the revised 2007 IDSA/ATS guidelines for the majority of patients with CAP, and thwart the use of a simple "one-size fits all" approach to patient care.
Since the publication of the initial IDSA Guidelines for the management of community acquired pneumonia in 2003, and their implementation by JHACO and the Centers for Medicare and Medicaid Services (CMS) in 2004 as a "quality standard" for hospital care and reimbursement, hospital administrators have been scrambling to improve their numbers.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.